U.S., Sept. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07163273) titled 'Monthly Alternating NALIRIFOX and GnP in the First-Line Setting' on July 14.
Brief Summary: A prospective, interventional, single-center, single-arm, open-label, phase II study for patients with metastatic pancreatic cancer. The intervention consists of monthly alternating standard chemotherapy regimens-NALIRIFOX and GnP. The hypothesis is that induction therapy with alternating NALIRIFOX and GnP has better efficacy compared to historical observation.
Study Start Date: June 20
Study Type: INTERVENTIONAL
Condition:
Pancreatic Ductal Adenocarcinoma
Intervention:
DRUG: NALIRIFOX
NALIRIFOX consists of 5-FU 2400 mg/m2 over 46 hou...